Salvinorin B

Salvinorin B is a selective and brain-penetrant kappa opioid receptor (KOPr) agonist with an EC₅₀ of 248 nM and K_i of 2.95 μM. Salvinorin B activates downstream signaling pathways by binding to KOPr, inhibits pain transmission and reduces inflammatory response. Salvinorin B can be used for the researches of inflammation, immunology and neurological disease, such as neuropathic pain, multiple sclerosis and anxiety^{[1][2][3][4][5]}. In Vivo:Salvinorin B is inert in vivo^[1].
Salvinorin B (β-tetrahydropyran Salvinorin B) (1-2 mg/kg, i.p.) reduces inflammation in formalin-induced inflammatory pain model models^[2].
Salvinorin B (β-tetrahydropyran Salvinorin B) (2 mg/kg, s.c.) supresses both mechanical and cold allodynia in Paclitaxel (HY-B0015)-induced neuropathic pain mice model^[2].
Salvinorin B (ethoxymethyl ether Salvinorin B) (0.1-0.3 mg/kg, i.p., daily) decreased disease severity in multiple sclerosis mice models^[3].
Salvinorin B (2-O-salvinorin B benzofuran-2-carboxylate) (1-30 mg/kg, p.o.) shows antinociceptive and anxiolytic-like effects in mice nociception and anxiety models^[4].
Salvinorin B (methyl ester Sal B) (0.3 mg/kg, i.p.) attenuates cocaine-induced hyperactivity and behavioral sensitization to cocaine^[5].